small molecule drug discovery based on orphan nuclear receptors

History:

X-Ceptor Therapeutics was acquired by Exelixis in 2004. Prior to the merger, Ligand Pharmaceuticals had a stake in X-Ceptor. Exelixis has maintained the San diego site.

Employment

Email:

Fax:

Mail:

General Info:

Ticker:

Employees:

Regions:
Southern California

Research Focus:
Disease Therapeutics-Research

 

Profiles:

 

News:

Keywords: 

Strategic Partnerships: